ReviewNature reviews. Disease primers2017
Chronic lymphocytic leukaemia.
Open access · greenAbstract readReview
In one paragraph
Review in Nature reviews. Disease primers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 288 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
288citing papers in PubMed, 1 pooled it
30.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
288 citing papers in PubMed, 1 synthesis or guideline pooled it, 503 citations in OpenAlex.
- Acute and Chronic Leukemia in Sub-Saharan Africa: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.Signal transduction and targeted therapy · 2026Trial
- Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.Blood cancer journal · 2026Trial
- Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study.International journal of hematology · 2026Trial
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Quality by design-based development of ibrutinib polymer-lipid hybrid nanoparticles for enhanced lymphatic absorption and anticancer efficacy.International journal of pharmaceutics: X · 2026Article
- Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report.American journal of ophthalmology case reports · 2026Article
- ZNF292 mutations impair RNA and protein biosynthesis defining an adverse prognostic subset in early-stage chronic lymphocytic leukemia.Biomarker research · 2026Article
- Integration of imaging-based and sequencing-based spatial omics mapping on the same tissue section via DBiTplus.Nature methods · 2026Article
- Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4.Apoptosis : an international journal on programmed cell death · 2026Article
- Cytogenetic Characteristics of Chronic Lymphocytic Leukemia Patients: A Single-Center Study From Morocco.Cureus · 2026Article
- ComplexInternational journal of molecular sciences · 2026Review
- A 3D lymph node model for chronic lymphocytic leukaemia recapitulates microenvironmental features and drug response in vitro.Disease models & mechanisms · 2026Article
- CCL19bioRxiv : the preprint server for biology · 2026Article
- Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemia.Leukemia · 2026Article
- Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.Genome biology · 2026Article
- Adverse Effects of Low Serum HDL-C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia.Cancer medicine · 2026Article
- Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort.Antibodies (Basel, Switzerland) · 2026Article
- Article
- Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026Article
228 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 9 institutions in 2 countries.
Thomas J KippsDivision of Hematology-Oncology, Department of Medicine, Moores Cancer Centre, University of California, San Diego, 3855 Health Sciences Drive M/C 0820, La Jolla, California 92093, USA.
Freda K StevensonSouthampton Cancer Research UK Centre, Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
Catherine J WuDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Carlo M CroceDepartment of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio, USA.
Graham PackhamSouthampton Cancer Research UK Centre, Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
William G WierdaDepartment of Hematology, MD Anderson Cancer Centre, Houston, Texas, USA.
Susan O'BrienDivision of Hematology, Department of Medicine, University of California, Irvine, California, USA.
John GribbenDepartment of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Kanti RaiCLL Research and Treatment Program, Feinstein Institute for Medical Research, Northwell Health, New Hyde Park, New York, USA.
Cancer Research UK · GBDana-Farber Cancer Institute · USNorthwell Health · USQueen Mary University of London · GBThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Irvine · USUniversity of California, San Diego · USUniversity of Southampton · GB
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6M(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MStatistical methods for analysis of single-cell variabilityR01HL131768 · NHLBI · HARVARD MEDICAL SCHOOL · PI KHARCHENKO, PETER V · 2015 to 2019
$2.4M(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLLR01CA184922 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2017
$2.2MThe role of the SF3B1 splicing factor in chronic lymphocytic leukemiaR01HL116452 · NHLBI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2013 to 2017
$2.1MDefining the impact of clonal evolution on chronic lymphocytic leukemiaR01CA182461 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2018
$1.8MCancer Research UK 23669NCI NIH HHS P01 CA081534NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA182461NCI NIH HHS R01 CA184922NCI NIH HHS R01 CA216273NCI NIH HHS U10 CA180861NHLBI NIH HHS R01 HL116452NHLBI NIH HHS R01 HL131768
Abstract
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.